SE9302414D0 - PEPTID WITH OXYTOCINANTAGONIST ACTIVITY - Google Patents

PEPTID WITH OXYTOCINANTAGONIST ACTIVITY

Info

Publication number
SE9302414D0
SE9302414D0 SE19939302414A SE9302414A SE9302414D0 SE 9302414 D0 SE9302414 D0 SE 9302414D0 SE 19939302414 A SE19939302414 A SE 19939302414A SE 9302414 A SE9302414 A SE 9302414A SE 9302414 D0 SE9302414 D0 SE 9302414D0
Authority
SE
Sweden
Prior art keywords
alpha
beta
acid residue
oxytocinantagonist
peptid
Prior art date
Application number
SE19939302414A
Other languages
Swedish (sv)
Other versions
SE9302414L (en
SE501678C2 (en
Inventor
*Aurell Carl-Johan
*Melin Per
*Nilsson Anders
*Trojnar Jerzy
Original Assignee
Ferring B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring B V filed Critical Ferring B V
Priority to SE9302414A priority Critical patent/SE501678C2/en
Publication of SE9302414D0 publication Critical patent/SE9302414D0/en
Priority to CN94192763A priority patent/CN1126999A/en
Priority to EP94921875A priority patent/EP0791012A1/en
Priority to AU72406/94A priority patent/AU676071B2/en
Priority to PL94312568A priority patent/PL312568A1/en
Priority to CA002163114A priority patent/CA2163114A1/en
Priority to JP7504493A priority patent/JPH09502427A/en
Priority to CZ9698A priority patent/CZ9896A3/en
Priority to PCT/SE1994/000674 priority patent/WO1995002609A1/en
Priority to HU9503768A priority patent/HUT74874A/en
Priority to IL11026794A priority patent/IL110267A0/en
Priority to ZA945090A priority patent/ZA945090B/en
Priority to TW083107195A priority patent/TW268009B/zh
Publication of SE9302414L publication Critical patent/SE9302414L/en
Publication of SE501678C2 publication Critical patent/SE501678C2/en
Priority to KR1019950705294A priority patent/KR960702848A/en
Priority to NO955059A priority patent/NO955059L/en
Priority to FI960119A priority patent/FI960119A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A peptide having formula (I) wherein Mpa is 3-mercaptopropionic acid residue (-S-CH2-CH2-CO-); X is D-tryptophan (D-Trp) or beta -(2-Naphtyl)-D-alanine (D-Nal); Ile is isoleucine; Y is alloisoleucine (alloIle) or (S)-2-Amino-3-ethyl-pentanoic acid (Ala( beta -Et2)); Asn is asparagine; alpha -Abu is alpha -aminobutyric acid residue (II) and N alpha MeOrn is N alpha -methyl-ornithine, is disclosed. The peptides may be used as an active ingredient in a medicament, especially in a pharmaceutical composition for therapeutic treatment of excessive uterus muscle contractions.
SE9302414A 1993-07-13 1993-07-13 Peptide with oxytocin antagonist activity and pharmaceutical composition containing said peptide SE501678C2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
SE9302414A SE501678C2 (en) 1993-07-13 1993-07-13 Peptide with oxytocin antagonist activity and pharmaceutical composition containing said peptide
EP94921875A EP0791012A1 (en) 1993-07-13 1994-07-07 Peptides exhibiting oxytocin antagonistic activity
PCT/SE1994/000674 WO1995002609A1 (en) 1993-07-13 1994-07-07 Peptides exhibiting oxytocin antagonistic activity
HU9503768A HUT74874A (en) 1993-07-13 1994-07-07 Peptides exhibiting oxytocin antagonistic activity and pharmaceutical compositions containing them as active component
AU72406/94A AU676071B2 (en) 1993-07-13 1994-07-07 Peptides exhibiting oxytocin antagonistic activity
PL94312568A PL312568A1 (en) 1993-07-13 1994-07-07 Peptides having antagonistic action in relation to oxytocin
CA002163114A CA2163114A1 (en) 1993-07-13 1994-07-07 Peptides exhibiting oxytocin antagonistic activity
JP7504493A JPH09502427A (en) 1993-07-13 1994-07-07 Peptides showing oxytocin antagonist activity
CZ9698A CZ9896A3 (en) 1993-07-13 1994-07-07 Peptide suppressing oxytocin activity
CN94192763A CN1126999A (en) 1993-07-13 1994-07-07 Peptides exhibiting oxytocin antagonistic activity
IL11026794A IL110267A0 (en) 1993-07-13 1994-07-11 Peptide exhibiting oxytocin antagonistic activity
ZA945090A ZA945090B (en) 1993-07-13 1994-07-13 Peptides exhibiting oxytocin antagonistic activity
TW083107195A TW268009B (en) 1993-07-13 1994-08-05
KR1019950705294A KR960702848A (en) 1993-07-13 1995-11-27 Peptides showing oxytocin antagonistic activity
NO955059A NO955059L (en) 1993-07-13 1995-12-13 Peptides showing oxytocin antagonistic activity
FI960119A FI960119A0 (en) 1993-07-13 1996-01-10 Peptides with oxitocin antagonizing activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9302414A SE501678C2 (en) 1993-07-13 1993-07-13 Peptide with oxytocin antagonist activity and pharmaceutical composition containing said peptide

Publications (3)

Publication Number Publication Date
SE9302414D0 true SE9302414D0 (en) 1993-07-13
SE9302414L SE9302414L (en) 1995-01-14
SE501678C2 SE501678C2 (en) 1995-04-10

Family

ID=20390606

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9302414A SE501678C2 (en) 1993-07-13 1993-07-13 Peptide with oxytocin antagonist activity and pharmaceutical composition containing said peptide

Country Status (16)

Country Link
EP (1) EP0791012A1 (en)
JP (1) JPH09502427A (en)
KR (1) KR960702848A (en)
CN (1) CN1126999A (en)
AU (1) AU676071B2 (en)
CA (1) CA2163114A1 (en)
CZ (1) CZ9896A3 (en)
FI (1) FI960119A0 (en)
HU (1) HUT74874A (en)
IL (1) IL110267A0 (en)
NO (1) NO955059L (en)
PL (1) PL312568A1 (en)
SE (1) SE501678C2 (en)
TW (1) TW268009B (en)
WO (1) WO1995002609A1 (en)
ZA (1) ZA945090B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604341D0 (en) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
EP1480998B1 (en) 2002-02-27 2006-11-22 Ferring BV Intermediates and methods for making heptapeptide oxytocin analogues
CN108290929A (en) 2015-10-06 2018-07-17 辉凌公司 Manufacture the novel method of barusiban and its intermediate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5373089A (en) * 1988-09-02 1994-12-13 Northwestern University Oxytocin antagonist
SE9002384D0 (en) * 1990-07-09 1990-07-09 Ferring Ab DERIVATIVE OF BACKGROUND HORMONES
SE501677C2 (en) * 1993-06-18 1995-04-10 Ferring Bv Biologically active vasopressin analogs, pharmaceutical preparations containing them and their use in the manufacture of drugs

Also Published As

Publication number Publication date
EP0791012A1 (en) 1997-08-27
HUT74874A (en) 1997-02-28
AU7240694A (en) 1995-02-13
KR960702848A (en) 1996-05-23
NO955059D0 (en) 1995-12-13
TW268009B (en) 1996-01-11
FI960119A (en) 1996-01-10
CN1126999A (en) 1996-07-17
IL110267A0 (en) 1994-10-21
SE9302414L (en) 1995-01-14
FI960119A0 (en) 1996-01-10
CZ9896A3 (en) 1996-06-12
JPH09502427A (en) 1997-03-11
WO1995002609A1 (en) 1995-01-26
CA2163114A1 (en) 1995-01-26
NO955059L (en) 1995-12-13
AU676071B2 (en) 1997-02-27
ZA945090B (en) 1995-02-22
PL312568A1 (en) 1996-04-29
SE501678C2 (en) 1995-04-10
HU9503768D0 (en) 1996-02-28

Similar Documents

Publication Publication Date Title
IL102848A0 (en) Polypeptides having growth hormone releasing activity,their use and pharmaceutical compositions containing them
ES2186693T3 (en) COMBINED USE OF HIALURONIC ACID AND THERAPEUTIC AGENTS TO IMPROVE THE THERAPEUTIC EFFECT.
MX9402339A (en) PROTEIN FORMULATION.
IL135258A0 (en) Bioadhesive compositions and methods for topical administration of active agents
DK0726768T3 (en) Use of nitric oxide releasing compounds in the manufacture of a medicament for protection in ischemic reperfusion
DE69914463D1 (en) Therapeutische chemokine rezeptor antagonisten
BRPI9708566A (en) glp-2 analog, glp-human peptide analog, peptide, pharmaceutical composition, use of a glp-2 analog, and, process for identifying intestinetrophic glp-2 analogs.
DE69527966D1 (en) PHARMACEUTICAL PREPARATION FOR SUBCUTANEOUS, INTRAMUSULAR OR INTRADERMAL ADMINISTRATION OF FACTOR VIII
MXPA02002895A (en) Topical treatment of streptococcal infections.
MY139203A (en) Pharmaceutical composition
MY109309A (en) Improvements in or relating to somatostatins
BR9811755A (en) Peptide, process for the treatment of obesity in an animal, use of a peptide, and pharmaceutical composition
AU9551201A (en) Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic diseasestates
FI956050A0 (en) Biologically active vasopressin analogues
BR0010983A (en) Preparations for the application of anti-inflammatory agents
SE9302414D0 (en) PEPTID WITH OXYTOCINANTAGONIST ACTIVITY
DK1309613T3 (en) A pharmaceutical composition comprising an analgesic peptide
KR960000921A (en) Calcitonin derivatives and uses thereof
ATE546461T1 (en) GNRH NON-MAMMAL ANALOGUE AND USE FOR REGULATION OF FERTILITY AND PREGNANCY
ES2149177T3 (en) COMPOSITIONS FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME.
ATE3416T1 (en) PHARMACOLOGICALLY ACTIVE PEPTIDES AND MEDICATIONS CONTAINING THEM.
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
ATE364392T1 (en) LIGAND/LYTIC PETIDE COMPOSITION AND USE THEREOF
ES2211996T3 (en) UNION AGENTS FOR HIALURONIC ACID RECEPTORS AND THEIR USE FOR TUMOR TREATMENT OR RESISTANCE.
TR200401810T4 (en) Use of fsh for infertility treatment

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 9302414-9

Format of ref document f/p: F